Denmark has solidified its position as a global life sciences powerhouse, distinguished by its world-leading pharmaceutical industry and a highly integrated healthcare innovation ecosystem.
The nation is best known for its dominance in metabolic diseases, particularly through the global success of GLP-1 therapies and insulin production, spearheaded by industry giants like Novo Nordisk. Beyond diabetes care, Denmark's biotechnology sector excels in biosolutions and enzyme technology, with companies such as Novonesis driving sustainable industrial applications.
The medical device and medtech landscape is equally robust, led by innovators like Coloplast and GN Hearing, who focus on chronic care and advanced hearing solutions.
At the heart of this success is Medicon Valley, one of Europe's most vibrant life science clusters, fostering seamless collaboration between academic research at institutions like the University of Copenhagen and private enterprise.
The country's clinical trial infrastructure is world-class, supported by unique health data registries that provide a goldmine for personalized medicine and epidemiological studies.
Furthermore, Denmark's public-private partnerships and the government's ambitious National Strategy for Life Science ensure a "red carpet" for foreign direct investment and manufacturing expansion. As a pioneer in digital health, Denmark continues to lead in hospital-at-home solutions and the integration of AI in drug discovery.
This comprehensive ecosystem, supported by the Novo Nordisk Foundation, makes Denmark a premier destination for life science careers and cutting-edge R&D.
Denmark's research environment is supported by leading institutions such as the University of Copenhagen, with 37,500 students and 5,000 researchers, and the Technical University of Denmark (DTU). DTU Science Park hosts over 300 companies in deep tech, while startup labs like CPHLabs and Symbion provide early-stage access to facilities and networks.
The Novo Nordisk Foundation is a key source of life science funding, supporting entrepreneurship and translational research. Together with EIFO (the Export and Investment Fund of Denmark), it co-funds the Life Science Without Borders program, which mobilises capital and cross-border partnerships to accelerate startup growth.
In 2024, venture capital (VC) investments in Denmark's life sciences (biotech, medtech, healthtech) totaled around $434 million (€375 million) across 22 rounds, down 45% from 2023 but still representing 33% of national VC activity. Foreign participation has grown: international investors were involved in 70% of Danish life science rounds in 2024, contributing 27% of total capital (up from 11% in 2023). Copenhagen continues to position itself as a European hub, supported by institutions such as the BioInnovation Institute and the Novo Nordisk Foundation.
Novo Nordisk committed around $450 million (DKK 2.9 billion) in 2024 toward a new quality-control laboratory in Hillerød, Denmark, enhancing its manufacturing and analytical capacity. At a regional level, Medicon Valley Alliance brings together over 300 members across Denmark and Sweden, reinforcing Copenhagen's cross-border life science cluster.
Denmark is recognised as one of the most digitalized health systems globally. Nearly all workflows across hospitals, general practitioners and municipalities are digital, with citizens accessing their records and prescriptions through the national e-health portal Sundhed.dk, which sees 2.3 million monthly unique visitors. Recent initiatives include telemedicine for pregnancy monitoring, AI-driven radiology in North Denmark emergency rooms (covering around 52,000 patients annually) and sensor-based systems like Teton.ai that have reduced patient falls by 83% while cutting routine nurse checks by 25%. In 2024, AI-driven healthtech attracted approximately $155.6 million (€133 million) across 23 companies, showing sustained investor interest in digital platforms despite reduced medtech deal volumes.
Denmark led the European Economic Area (EEA) in 2023 for per-capita commercial clinical trial starts (2.00 per 100,000 people); it is also cited among the fastest countries on enrolment timelines and appears in the top 10 for single-country commercial trials (13 starts; 4% share). Denmark is advancing in decentralised clinical trials (DCTs) through the approximately $5.85 million (€5 million) PACT project (2022 to 2026), a public-private collaboration led by Innovation Fund Denmark with partners including Trial Nation, IQVIA, Roche and Novartis. The initiative develops operational frameworks for patient-centred digital and decentralized trials, making participation possible from home or local care settings. The Danish Clinical Quality Program (RKKP) oversees 85 national clinical registries, integrating nationwide health data to track treatment efficacy, safety and mortality across disease areas.
Copenhagen, Denmark
Life sciences exports from Denmark rose from around $10.2 billion (DKK 65 billion) in 2010 to about $27.3 billion (DKK 174 billion) in 2023 and accounted for roughly 20% of total Danish goods exports in 2023; Danish-owned companies abroad exported approximately a further $16.88 billion (DKK 107.7 billion) in life science goods the same year. Domestically, the sector employed about 63,000 FTEs or Full-Time Equivalents in 2021 (up about 43% since 2010). The Danish pharmaceutical sector is forecast to expand by 1.7% in 2025 and 2.3% in 2026, following a period of slower growth in 2024.
The sector employs over 50,000 people across Denmark, with SMEs (small and medium sized businesses) making up 99% of firms. The workforce shows a near-equal gender split in leadership and technical roles. A growing number of SMEs are patent-active, highlighting innovation potential among smaller firms.
Denmark reinforced its development infrastructure with around $9.4 million (DKK 60 million) allocated in 2025 to expand test, development and demonstration facilities for precision fermentation and CO₂‑to‑protein technologies. Highlighted infrastructure includes the Biosolutions Technology Center (BTC), equipped with food‑compliant labs and a 2,000 L biofermentation pilot plant, and FermHub Zealand, the country's largest biosolutions demonstration site, featuring bioreactors up to 5,000 L.
Global players Novo Nordisk and Novozymes account for around 25% of all Danish life science patent filings. Denmark ranked 10th globally in the 2024 Global Innovation Index, placing 7th in innovation inputs and 12th in outputs. The country's strengths include information and communications technology (ICT) access (ranked 1st worldwide), rule of law (2nd) and scientific publishing, with Denmark producing the second-highest volume of scientific and technical articles relative to GDP. It also ranks 3rd for researchers per capita, with 8,736 full-time researchers per million people in 2022. Copenhagen appears as a top global science and technology cluster (ranked 16th by intensity, 57th overall), with particular strength in medical technology patents and engineering research.
Claim Profile to Update Website
Claim Profile to Update Contact Information
Claim Your Profile to Add Related Links
Claim Your Profile to add downloadable documentation
https://pharmaville.com/wp-content/uploads/2026/02/Pharmaville-Denmark-references.pdf
